# Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

> **NCT04223765** · PHASE1 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Mantle Cell Lymphoma
- Follicular Lymphoma
- Splenic Marginal Zone Lymphoma
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Nodal Marginal Zone Lymphoma
- Indolent Non-hodgkin Lymphoma

## Interventions

- **DRUG:** CAR.k.28
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04223765
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-12
- **Primary completion:** 2028-03-22
- **Final completion:** 2043-03-22
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04223765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04223765, "Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04223765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*